MLTX
NASDAQ · Biotechnology
Moonlake Immunotherapeutics
$17.45
+0.74 (+4.43%)
Open$17.03
Previous Close$16.71
Day High$17.51
Day Low$16.88
52W High$62.75
52W Low$5.95
Volume—
Avg Volume1.29M
Market Cap1.30B
P/E Ratio—
EPS$-3.33
SectorBiotechnology
Analyst Ratings
Buy
23 analysts
Price Target
-39.6% upside
Current
$17.45
$17.45
Target
$10.54
$10.54
$8.06
$10.54 avg
$16.98
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 207.37M | 195.61M | 178.47M |
| Net Income | -41,056,867 | -38,376,149 | -44,335,912 |
| Profit Margin | -19.8% | -19.6% | -24.8% |
| EBITDA | -81,449,014 | -69,654,675 | -60,804,840 |
| Free Cash Flow | -45,845,658 | -33,391,408 | -32,934,200 |
| Rev Growth | +19.2% | +9.7% | +1.7% |
| Debt/Equity | 0.11 | 0.10 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |